Resources

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Nature Scientific reports, Vol. 9, Issue 1, Pages 18793, 2019

PMID: 31827134

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge.

Read More

  https://www.ncbi.nlm.nih.gov/pubmed/31827134

 

Considering Genomic Research?

    Fields marked in * is mandatory to fill
     
     
     

    2024 © MedGenome • All Rights Reserved
    Request a Quote